Companion diagnostic requirements for spatial biology using multiplex immunofluorescence and multispectral imaging

Area of Science:

• Biomarker discovery and validation in oncology
• Tumor microenvironment and immuno-oncology research
• Development of predictive assays for targeted therapies

Background:

• Traditional immunohistochemistry (IHC) using single markers is insufficient for complex cancer biology.
• The tumor microenvironment's spatial context is crucial for predicting treatment response.
• Personalized medicine demands more precise and efficient diagnostic tools.

Purpose of the Study:

• To explore the requirements for developing clinical multiplex immunofluorescence (mIF) assays.
• To evaluate the Akoya Phenoptics workflow for predictive biomarker testing.
• To discuss regulatory, safety, and quality aspects of mIF assays for clinical use.

Main Methods:

• Review of scientific, clinical, and economic needs for mIF assay development.
• Assessment of the Akoya Phenoptics platform's capabilities for predictive testing.
• Analysis of regulatory pathways for lab-developed tests and in vitro diagnostics.

Main Results:

• Multiplex methods, including immunofluorescence, provide deeper insights than single-marker IHC.
• Spatial relationships between biomarkers are critical for understanding treatment efficacy.
• Data-driven approaches are essential for advancing precision medicine in immuno-oncology.

Conclusions:

• Multiplex immunofluorescence assays are vital for advancing personalized cancer treatment.
• Understanding the foundation and application of mIF is key for regulated diagnostic use.
• This technology supports the development of predictive tests for novel therapies.